A phase I single site, single dose, randomized, double-blind, placebo controlled, 3-way cross-over biomarker study investigating the effect of the GABA modulator AZD7325 on cutaneous sensation in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2016
At a glance
- Drugs AZD 7325 (Primary)
- Indications Anxiety disorders
- Focus Therapeutic Use
- 26 Jul 2016 Status changed from recruiting to completed.
- 02 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 13 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov